摘要
原发性胆汁性胆管炎是一种慢性肝内胆汁淤积性疾病,其病理特征为肝内胆管进行性破坏,实验室检查可见ALP和GGT升高、抗线粒体抗体(AMA)阳性,目前西医治疗原发性胆汁性胆管炎的一线药物是熊去氧胆酸,但仍有部分患者对熊去氧胆酸治疗应答不佳,中医辨证论治在本病的治疗中有一定优势。施卫兵教授结合多年临床治疗经验,认为原发性胆汁性胆管炎的病因病机可概括为气滞、瘀血、湿热、本虚,治疗时应根据病机演变,切合病机立法用药,随证加减。
Biliary cholangitis is a chronic intrahepatic cholestasis disease.Its pathological feature is the progressive destruction of the intrahepatic bile ducts.Laboratory tests show elevated ALP and GGT and positive anti-mitochondrial antibodies(AMA).The first-line drug for the treatment of primary biliary cholangitis is ursodeoxycholic acid,but there are still some patients who do not respond well to ursodeoxycholic acid treatment,and TCM syndrome differentiation has certain advantages in the treatment of this disease.Professor SHI Weibing combined with many years of clinical treatment experience,he believes that the etiology and pathogenesis of primary biliary cholangitis can be summarized as Qi stagnation,blood stasis,damp heat,and deficiency.The treatment should be based on the evolution of the pathogenesis,and should be used in accordance with the pathogenesis legislation.Card addition and subtraction.
作者
马翠翠
施卫兵
MA Cuicui;SHI Weibing(Anhui University of Chinese Medicine,Anhui Hefei 230038,China;The First Affiliated Hospital of Anhui University of Chinese Medicine,Anhui Hefei 230031,China)
出处
《中医药临床杂志》
2020年第4期632-635,共4页
Clinical Journal of Traditional Chinese Medicine
关键词
原发性胆汁性胆管炎
病因病机
经验
施卫兵
Primary biliary cholangitis
Etiology and pathogenesi
Experience
SHI Weibing
